Resumen de: WO2019055234A1

Provided herein are pharmaceutical compositions for local administration of metabolic inhibitors, methods of locally administering such compositions, and rapid diagnostic methods for identifying mutant allele during the course of a surgical procedure Aspects of the present disclosure provide pharmaceutical compositions comprising a population of particles coupled to a nicotinamide adenine dinucleotide (NAD) biosynthesis inhibitor. Other aspects of the present disclosure provide methods of local administration of a metabolic inhibitor, comprising locally administering a therapeutically effective amount of any of the pharmaceutical compositions described herein to a subject in need thereof. Other aspects of the present disclosure provide diagnostic methods comprising obtaining a sample from a subject; and detecting one or more mutations in a target nucleic acid in the sample; wherein the detecting is performed by isolating a nucleic acid comprising the target nucleic acid from the sample, and analyzing the nucleic acid for the presence of one or more allele-specific mutations; and wherein the detecting is performed in an intraoperative timeframe. Other aspects of the present disclosure provide methods of diagnosis and treatment of a cancer in a subject, comprising performing a surgical procedure on the subject; obtaining a sample from the subject; and determining whether the sample contains a one or more mutations in a target nucleotide sequence in the sample; wherein if the sa

Resumen de: US2019083638A1

Disclosed herein are conjugates of a therapeutic compound and polypeptides, such as a conjugate of niclosamide and an elastin-like polypeptide. These conjugates may form nanoparticles through self-assembly, which improve the solubility, bioavailability, and pharmacokinetic profiles of the therapeutic compound. Also disclosed are methods for treating cancer, parasite infection, bacterial infection, viral infection, metabolic diseases, Type II diabetes, NASH, NAFLD, artery constriction, endometriosis, neuropathic pain, rheumatoid arthritis, sclerodermatous graft-versus-host disease, and systemic sclerosis.

Resumen de: WO2019053269A1

The invention relates to a hybrid hydrogel, in particular degradable or non-degradable, comprising a first hydrogel polymer of formula (I) in association with an alginate hydrogel polymer, and optionally organosilica particles in particular degradable or non-degradable nanoparticles, or porous silicon particles; pharmaceutical, veterinary and/or cosmetic compositions thereof; and uses thereof as a medicament. The invention notably relates to the use of such hybrid hydrogel in the treatment of fistulas and physiological leaks/leakages, notably in the gastrointestinal tract. The present invention finds applications in the therapeutic and diagnostic medical technical fields and also in cosmetic and veterinary technical fields.

Resumen de: WO2019055901A1

Disclosed herein is a particle containing an inner liposomal vesicle (ILV) encapsulating a therapeutic agent; an outer liposomal vesicle (OLV) encapsulating the ILV; a membrane fusion-promoting agent; and a pH-altering agent. Also disclosed are methods of delivering a therapeutic agent to a subject comprising: a) providing a herein disclosed particle b) triggering ILV and OLV fusion; and c) releasing the therapeutic agent outside of the OLV. Also disclosed are methods for treating a disease in a subject in need thereof comprising: administering to a subject a herein disclosed particle. Also disclosed are methods to release insulin to an environment comprising increased glucose levels, the method comprising exposing to the environment a herein disclosed particle.

Resumen de: WO2019055525A1

The present invention provides pharmaceutical compositions composed of solid nanoparticles dispersed in aqueous medium of substantially water insoluble pharmaceutical substances with reduced Ostwald ripening.

Resumen de: WO2019055958A1

Described herein are methods and compositions relating to methods of inhibiting neutrophils, e.g., inhibiting NET release or NETosis, by means of a DEspR inhibitor, e.g., an anti-DEspR antibody reagent. In some embodiments, the methods can relate to the treatment of a disease, e.g., cancer or a disease wherein neutrophils; NETs; or NETosing or NETting neutrophils contribute to pathogenesis, chronicity, or worsening of disease. In some embodiments, the DEspR inhibitor can be a bi-specific reagent or an antibody-drug conjugate.

Resumen de: WO2019054669A1

The present invention relates to a composition for oral cleaning having antimicrobial activity against oral microorganisms, containing a nano-capsule containing a natural antimicrobial extract as an active ingredient; a pharmaceutical composition for prevention or treatment of periodontal diseases; and a functional health food for prevention or improvement of periodontal diseases. The nano-capsule containing a natural antimicrobial extract and the composition for oral use comprising the same according to the present invention have effects such as greatly increasing antimicrobial activity by collecting a complex of natural extracts exhibiting a synergistic effect; increasing the adhesion ability of the oral mucosa by controlling a coating characteristic of the capsule; and providing the composition for oral use that is capable of sustaining antimicrobial activity in the oral cavity for a long time by confirming a synergistic effect between the natural extracts and the nano-capsule. Thus, the composition for oral use of the present invention can be used as a safe antimicrobial product for dental health by being applied as a composition for oral cleaning, various food groups, or a pharmaceutical composition.

Resumen de: WO2019051733A1

Provided is a method for preparing an etoposide micelle, the method involving the following steps: dissolving 3-5 parts of VP-16 and 6-12 parts of TPGS in 20-30 parts of methanol, mixing same until uniform, and evacuating same at 30°C-40°C for rotary evaporation to remove the solvent to prepare a homogeneous mixed thin film containing the VP-16 and TPGS; and adding 80-90 parts of ultrapure water, shaking same in a water bath at 90°C -100°C to prepare a clear, transparent solution, filtering the solution with a micropore filter membrane while same is still hot, and freeze drying same in a vacuum to obtain the etoposide micelle, wherein each of the raw materials is in part by weight. The prepared VP-16-TPGS micelle has a smaller particle size, a higher drug loading capacity and encapsulation efficiency, and economic value.

Resumen de: US2019085332A1

Disclosed are short DNA aptamers that selectively recognize CD200R1, a protein expressed on the surface of myeloid and lymphoid cells that delivers immune inhibitory signals to modulate inflammation when engaged with its ligand, CD200. Also disclosed is the use of said aptamers as therapeutic agents, for the purpose of decreasing inflammatory response; treatment of spinal cord injury; treatment of an immune related disease such as arthritis, asthma, allergy, infection; as a course of treatment during or after transplantation; or for treatment of an autoimmune disorder such as systemic lupus erythematosus, Parkinson's Disease, or multiple sclerosis.

Resumen de: US2019083666A1

Portable multifunctional device designed for sanitizing of inner and outer surfaces of shoes, sanitizing of air, water, household items and surfaces, treatment of skin and wound infection, nails fungus, cosmetic use, and detection of counterfeit currency. The device is able to perform all the above sanitizing, therapeutic and cosmetic functions that would otherwise be carried out by various different devices. The enhance functionality has been accomplished without alteration of any parts of the device. Apparatus utilizes light radiation in three diapasons: 100-280, 405-495, and 700-1064 nm and provides distant sanitizing. Apparatus comprises at least one module with a dual DC-AC power supply. Each module has a germicidal unit, retractable flexible shaft, shade, and housing. The flexible shaft allows positioning the germicidal units under different angle for uniform distant illumination. The device is suitable for household, traveling, and military use.

Resumen de: US2019085034A1

Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, comprising conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.

Resumen de: US2019083574A1

Thermogenic molecules and methods of using these molecules for treating or preventing a condition in a subject selected from the group consisting of visceral fat accumulation (e.g., Crohn's disease associated with visceral fat accumulation), obesity, diabetes, pre-diabetes, hypothermia, and chronic inflammation are disclosed. Also disclosed is a method for promoting glucose uptake in peripheral tissues (e.g., adipocytes and muscles) of a subject, enhancing nerve innervation in a subject, activating PI3 kinase in cell, and inducing leptin secretion by an adipocyte. Also disclosed are inhibitors of thermogenic molecules and methods of using these inhibitors to decrease thermogenesis of adipocytes in a subject. Also disclosed are self-assembled, biocompatible nanostructure non-covalently associated with a therapeutic or diagnostic peptide or peptidomimetic.

Resumen de: US2019083518A1

Disclosed are compositions and methods for treating, amelioriating, reversing and/or preventing (acting as a prophylaxis): a respiratory condition involving an infection or an inflammation, or any lung condition involving inflammation or infection, e.g., of a respiratory mucosa, and/or an infection or an inflammation of an underlying muscle of the respiratory tract; or, an asthma; a bronchitis; a sinusitis or rhinosinusitis; an infection of a sinus; chronic obstructive airway disease; emphysema; chronic bronchitis; pneumonia; or, a bronchiectasis. In alternative embodiments, the therapeutic combination comprises an orally administered Amphotericin B or equivalent antifungal alone, or a combination of Amphotericin B and: one antibiotic; two antibiotics; three antibiotics; or, four or more antibiotics. In alternative embodiments, these compositions and methods are dosaged and administered to children in need thereof. In alternative embodiments, compositions and methods of the invention are dosaged, formulated and dosaged as tablet, capsule, liquid, powder or aerosol preparations or formulations, or preparations or formulations for oral delivery or inhalation.

Resumen de: US2019083576A1

The present disclosure provides compositions and methods for efficient and effective protein delivery in vitro and in vivo. In some aspects, proteins are reversibly crosslinked to each other and/or modified with functional groups and protected from protease degradation by a polymer-based or silica-based nanoshell.

Resumen de: US2019083637A1

Disclosed is a drug conjugate as a prodrug that is degraded by cathepsin B specifically expressed in tumor tissues to release doxorubicin. The drug conjugate can form self-assembled nanoparticles. In addition, the drug conjugate specifically responds to and is activated in tumor cells. Therefore, the use of the drug conjugate eliminates the incidence of side effects (for example, cell damage and apoptosis) during the course of cancer prevention or treatment.

Resumen de: US2019083490A1

The present invention relates to a comprising (A) an active ingredient which is hardly soluble in water, but soluble in a C1-4 lower alcohol that may contain 30 vol % or less water, (B) polyvinyl alcohol having a saponification rate of 55-99%, and (C) a non-ionic surfactant, wherein the (A) active ingredient has a mean particle size of 10-300 nm, and a process thereof.

Resumen de: US2019083367A1

Provided are coated particles and methods of their use for providing healthcare benefits. More specifically, the present invention provides amino acid and/or polymer-coated particles, or particles coated with other materials, for binding to, or otherwise associating with, surfaces of the oral cavity.

Resumen de: US2019083389A1

Disclosed herein is a device and method for regenerating tissue using a modular scaffold having a gradient of enzymatic degradability. The disclosure further relates to scaffolds made of microparticles comprising a cross-linked water-soluble polymer or cross-linked water-soluble polymers and a process for forming thereof.

Resumen de: US2019083415A1

Provided is a sustained release sheet that includes a drug for treating nerve injury, wherein the sheet is applied to a nerve injury site, can maintain a high concentration of the drug over a long period, and promotes nerve regeneration without stimulating the nerves, even when the sheet is implanted in the periphery of the nerve injury site. Also provided is a production method for the sheet. This sustained drug release sheet for treating nerve injury is a sheet comprising a non-woven fabric that is formed from nanofibers each containing a drug such as vitamin B12 and a biocompatible polymer such as a biodegradable aliphatic polyester, and is implanted in the periphery of the nerve injury site to promote nerve regeneration.

Resumen de: US2019083414A1

The invention concerns nanocapsules in the form of a colloidal suspension or in dry form, said nanocapsules comprising at least an active ingredient in the form of an oil, one ionic surfactant, optionally one nonionic surfactant, and one hydrophilic polymer. The invention also concerns their manufacture and their uses.

Resumen de: US2019083569A1

A composition is provided comprising an electrospun fiber having a surface with a biological adhesive moiety conjugated to the surface of the electrospun fiber. The biological adhesive moiety included in the composition can be a lectin such as griffithsin. The composition can further include an effective amount of an antiviral agent encapsulated by an electrospun fiber. Nanoparticles including a microbicide conjugated to the surface of the nanoparticle can also be included in the composition. Methods of treating a viral infection are also provided and include administering to a subject an effective amount of a composition comprising an electrospun fiber having a surface and a biological adhesive moiety conjugated to the surface of the electrospun fiber.

Resumen de: US2019083649A1

The invention provides powerful methods and compositions for designing, selecting, fine-tuning and optimizing polymer nanogel and other supramolecular assemblies for various properties including, for example, particle size, density and morphology, guest loading capacity and encapsulation stability, and dynamic release control.

Resumen de: US2019085312A1

A treatment method is provided in which glioblastoma is targeted by administering to a subject in an effective amount theranostic cross-linked iron oxide nanoparticles (CLIO) which are conjugated to a vascular disrupting agent (ICT) and secured with a matrix-metalloproteinase cleavable peptide.

Resumen de: US2019083595A1

Described herein are methods and compositions relating to methods of inhibiting neutrophils, e.g., inhibiting NET release or NETosis, by means of a DEspR inhibitor, e.g., an anti-DEspR antibody reagent. In some embodiments, the methods can relate to the treatment of a disease, e.g., cancer or a disease wherein neutrophils; NETs; or NETosing or NETting neutrophils contribute to pathogenesis, chronicity, or worsening of disease. In some embodiments, the DEspR inhibitor can be a bi-specific reagent or an antibody-drug conjugate.

Resumen de: US2019083522A1

The present disclosure provides, in some aspects, nucleic acid-based biosynthetic modules for the production of ribonucleic acid (RNA) and other biopolymers.